{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:30:25Z","timestamp":1791318625646,"version":"4.3.1"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,5,7]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Etanercept is commonly used to treat juvenile idiopathic arthritis, including juvenile psoriatic arthritis (JPsA); however, information on etanercept\u2019s safety and effectiveness in clinical practice is limited. We used data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry to evaluate etanercept\u2019s safety and effectiveness in JPsA in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed safety and effectiveness data for paediatric patients enrolled in the CARRA Registry who had a JPsA diagnosis and had used etanercept. Safety was assessed by calculating rates of prespecified adverse events of special interest (AESIs) and serious adverse events (SAEs). Effectiveness was assessed by a variety of disease activity measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 226 patients had JPsA and received etanercept; 191 met criteria for safety analysis and 43 met criteria for effectiveness analysis. AESI and SAE incidence rates were low. There were five events: three uveitis, one new-onset neuropathy and one malignancy. Incidence rates were 0.55 (95% CI: 0.18, 1.69), 0.18 (95% CI: 0.03, 1.29) and 0.13 (95% CI: 0.02, 0.09) per 100 patient-years for uveitis, neuropathy and malignancy, respectively. Etanercept showed effectiveness for JPsA treatment; 7 of 15 (46.7%) had an American College of Rheumatology-Pediatric Response 90, 9 of 25 (36.0%) had a clinical Juvenile Arthritis Disease Activity Score 10-joint \u22641.1 and 14 of 27 (51.9%) had clinically inactive disease at the 6-month follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Data in the CARRA Registry showed that etanercept treatment was safe in treating children with JPsA, with low AESIs and SAEs. Etanercept was also effective, even when assessed in a small sample size.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002943","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:23:05Z","timestamp":1685020985000},"page":"e002943","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-1936","authenticated-orcid":false,"given":"Colleen K","family":"Correll","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Stryker","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Phillips","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C","family":"Dennos","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Balevic","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"2025090312003108000_9.2.e002943.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180131"},{"key":"2025090312003108000_9.2.e002943.2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12969-017-0160-6","article-title":"The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Design, rationale, and characteristics of patients enrolled in the first 12 months","volume":"15","author":"Beukelman","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"2025090312003108000_9.2.e002943.3","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2025090312003108000_9.2.e002943.4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/anr.1780320810","article-title":"Psoriatic arthritis in children","volume":"32","author":"Southwood","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2025090312003108000_9.2.e002943.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160717"},{"key":"2025090312003108000_9.2.e002943.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.22173"},{"key":"2025090312003108000_9.2.e002943.7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: A tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312003108000_9.2.e002943.8","doi-asserted-by":"publisher","DOI":"10.1080\/17402520600877802"},{"key":"2025090312003108000_9.2.e002943.9","unstructured":"US Food and Drug Administration . Cosentyx\u00ae (secukinumab) Prescribing Information. Novartis Pharmaceutical Corporation. Original issue 2015. 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504s043lbl.pdf [Accessed 10 Mar 2023]."},{"key":"2025090312003108000_9.2.e002943.10","unstructured":"European Medicines Agency. Enbrel\u00ae (etanercept) Prescribing Information. Pfizer Europe MA EEIG. 2009. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_en.pdf [Accessed 10 Mar 2023]."},{"key":"2025090312003108000_9.2.e002943.11","unstructured":"US Food and Drug Administration . Enbrel\u00ae (etanercept) Prescribing Information. Amgen Inc. 2012. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf [Accessed 10 Mar 2023]."},{"key":"2025090312003108000_9.2.e002943.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202031"},{"key":"2025090312003108000_9.2.e002943.13","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/art.11398","article-title":"Measures of pediatric function: The Child Health Assessment Questionnaire (CHAQ), Juvenile Arthritis Functional Assessment Report (JAFAR), Juvenile Arthritis Functional Assessment Scale (JAFAS), Juvenile Arthritis Functional Status Index (JASI), and Pediatric Orthopedic Surgeons of North America (POSNA) Pediatric Musculoskeletal Functional Health Questionnaire","volume":"49","author":"Klepper","year":"2003","journal-title":"Arthritis Care & Research"},{"key":"2025090312003108000_9.2.e002943.14","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2025090312003108000_9.2.e002943.15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/acr.22393","article-title":"Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score","volume":"66","author":"Consolaro","year":"2014","journal-title":"Arthritis Care & Research"},{"key":"2025090312003108000_9.2.e002943.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2025090312003108000_9.2.e002943.17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2025090312003108000_9.2.e002943.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223357"},{"key":"2025090312003108000_9.2.e002943.19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.rdc.2021.07.012","article-title":"Pharmacosurveillance in juvenile idiopathic arthritis","volume":"47","author":"Shiff","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312003108000_9.2.e002943.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long-term safety and effectiveness of etanercept in JIA: An 18-year experience from the BiKeR Registry","volume":"22","author":"Armaroli","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312003108000_9.2.e002943.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212613"},{"key":"2025090312003108000_9.2.e002943.22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: Data from the Biologics in Pediatric Rheumatology Registry","volume":"67","author":"Foeldvari","year":"2015","journal-title":"Arthritis Care & Research"},{"key":"2025090312003108000_9.2.e002943.23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22649","article-title":"Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: Longitudinal analysis from a nationwide pediatric rheumatology database","volume":"68","author":"Tappeiner","year":"2016","journal-title":"Arthritis Care & Research"},{"key":"2025090312003108000_9.2.e002943.24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/acr.23783","article-title":"Prospective determination of the incidence and risk factors of new-onset uveitis in juvenile idiopathic arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort","volume":"71","author":"Lee","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312003108000_9.2.e002943.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1916-9","article-title":"Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial","volume":"21","author":"Foeldvari","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312003108000_9.2.e002943.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203046"},{"key":"2025090312003108000_9.2.e002943.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150430"},{"key":"2025090312003108000_9.2.e002943.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00625-y","article-title":"Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"19","author":"Beukelman","year":"2021","journal-title":"Pediatr Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:00:38Z","timestamp":1756926038000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/rmdopen-2022-002943"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002943","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}